Clinical Trial Update: Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study assessing bioequivalence between two formulations of biphasic insulin aspart 70 in healthy subjects; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Biphasic insulin aspart 70 (insulin aspart, biphasic 70/30)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED